三生製藥(01530.HK)上周斥1,250萬元於市場上回購近150萬股
三生製藥(01530.HK)公布,公司於今年2月27日及2月28日,分別以介乎每股7.89元至8.73元回購合共149.35萬股股份,佔公司已發行股本0.06%,就股份購回的已付總買入價為1,250.6萬元。公司澄清指,公司董事及高級管理層一直保持穩定,7名董事中有5名自公司於聯交所上市起一直履行董事會職務。對於新冠病毒疫情,公司指雖然若干產品的生產暫時中止一段短暫的時間,但集團已恢復正常營運超過兩星期,因此公司預期先前暫時中止生產對集團業務營運及承擔並無造成任何重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.